Evaluation of antipsychotic dose reduction in late-life schizophrenia: A prospective dopamine D2/3 receptor occupancy study

JAMA Psychiatry

Volumn 72, Issue 9, 2015, Pages 927-934

  Graff Guerrero, Ariel ^a,b   Rajji, Tarek K ^a,b   Mulsant, Benoit H ^a,b   Nakajima, Shinichiro ^a,b,c   Caravaggio, Fernando ^a,b   Suzuki, Takefumi ^c   Uchida, Hiroyuki ^a,c   Gerretsen, Philip ^a,b   Mar, Wanna ^a   Pollock, Bruce G ^a,b   Mamo, David C ^d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c KEIO UNIVERSITY   (Japan)

^d UNIVERSITY OF MALTA   (Malta)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; OLANZAPINE; PALIPERIDONE; PROLACTIN; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; CARBON; NEUROLEPTIC AGENT; RACLOPRIDE;

ADULT; AGED; BARNES AKATHISIA SCALE; BRAIN MALFORMATION; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; INCIDENTAL FINDING; LATE LIFE SCHIZOPHRENIA; MALE; MONOTHERAPY; ONSET AGE; OPEN STUDY; OUTPATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITRON EMISSION TOMOGRAPHY; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; RECEPTOR OCCUPANCY; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UKU SIDE EFFECT RATING SCALE; BLOOD; BRAIN; CHEMICALLY INDUCED; EXTRAPYRAMIDAL SYNDROME; METABOLISM; MIDDLE AGED; NEOSTRIATUM;

AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BRAIN; CARBON RADIOISOTOPES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOSTRIATUM; POSITRON-EMISSION TOMOGRAPHY; PROLACTIN; PROSPECTIVE STUDIES; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84940974184     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.0891     Document Type: Conference Paper

References (39)

1. Uchida H, Suzuki T, Mamo DC, et al. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: A survey of 1, 418 patients in Japan. Am J Geriatr Psychiatry. 2008;16(7):584-593.
2. Sproule BA, Lake J, Mamo DC, Uchida H, Mulsant BH. Are antipsychotic prescribing patterns different in older and younger adults? a survey of 1357 psychiatric inpatients in Toronto. Can J Psychiatry. 2010;55(4):248-254.
3. Jeste DV, Maglione JE. Treating older adults with schizophrenia: challenges and opportunities. Schizophr Bull. 2013;39(5):966-968.
4. Suzuki T, Remington G, Uchida H, Rajji TK, Graff-Guerrero A, Mamo DC. Management of schizophrenia in late life with antipsychotic medications: A qualitative review. Drugs Aging. 2011;28(12):961-980.
5. Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65(suppl 2):5-99.
6. Uchida H, Kapur S, Mulsant BH, Graff-Guerrero A, Pollock BG, Mamo DC. Sensitivity of older patients to antipsychotic motor side effects: A PET study examining potential mechanisms. Am J Geriatr Psychiatry. 2009;17(3):255-263.
7. Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C, Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol. 1995;15(1)(suppl 1):19S-23S.
8. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia.Am J Psychiatry. 2000;157(4):514-520.
9. Ismail Z, Wessels AM, Uchida H, et al. Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry. 2012;20(1):53-60.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. ed 4. Washington, DC: American Psychiatric Association; 1994.
11. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
12. Grisso T, Appelbaum PS, Hill-Fotouhi C. The MacCAT-T: A clinical tool to assess patients' capacities to make treatment decisions. Psychiatr Serv. 1997;48(11):1415-1419.
13. Overall J, Gorham D. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:790-812.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. DHEW Publication No. ADM 76-338. Rockville, MD: US Dept of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976:218-222.
15. Suzuki T, Uchida H, Nomura K, et al. Novel rating scales for schizophrenia-Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). Schizophr Res. 2008;106(2-3):328-336.
16. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
17. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
18. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(suppl 3):133-138.
19. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU Side Effect Rating Scale: A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
20. Uchida H, Suzuki T, Graff-Guerrero A, et al. Therapeutic window for striatal dopamine D2/3 receptor occupancy in older patients with schizophrenia: A pilot PET Study. Am J Geriatr Psychiatry. 2014;22(10):1007-1016.
21. Peluso MJ, Lewis SW, Barnes TR, Jones PB. Extrapyramidal motor side-effects of first- And second-generation antipsychotic drugs. Br J Psychiatry. 2012;200(5):387-392.
22. Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev. 2008;60(3):358- 403.
23. Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm. 1992;11(10):851-856.
24. Wilson AA, Garcia A, Jin L, Houle S. Radiotracer synthesis from [11C]-iodomethane: A remarkably simple captive solvent method. Nucl Med Biol. 2000;27(6):529-532.
25. Graff-Guerrero A, Willeit M, Ginovart N, et al. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans. Hum Brain Mapp. 2008;29(4):400-410.
26. Studholme C, Hill DL, Hawkes DJ. Automated three-dimensional registration ofmagnetic resonance and positron emission tomography brain images by multiresolution optimization of voxel similarity measures. Med Phys. 1997;24(1):25-35.
27. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4(3, pt 1):153-158.
28. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27(9):1533-1539.
29. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage. 1997;6(4): 279-287.
30. Mawlawi O, Martinez D, Slifstein M, et al. Imaging human mesolimbic dopamine transmission with positron emission tomography, I: Accuracy and precision of D2 receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001; 21(9):1034-1057.
31. Nakajima S, Caravaggio F, Mamo DC, et al. Dopamine D2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [11 C]-raclopride PET study. Schizophr Res. 2015;164(1-3):263-267.
32. Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: A systematic review. Psychol Med. 2009;39(7):1065-1076.
33. Szewczyk-Krolikowski K, Tomlinson P, Nithi K, et al. The influence of age and gender on motor and non-motor features of early Parkinson's disease: Initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord. 2014;20(1):99-105.
34. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs: A systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31(3): 318-325.
35. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics, I: preliminary results for relapse rates. Arch Gen Psychiatry. 1983;40(8):893-896.
36. Hogarty GE, McEvoy JP, Munetz M, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: Results of a two-year controlled study. Arch Gen Psychiatry. 1988;45(9): 797-805.
37. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalization during maintenance treatment of schizophrenia: The effects of dose reduction and family treatment. Arch Gen Psychiatry. 1997;54(5):453-463.
38. Sapra M, Vahia IV, Reyes PN, Ramirez P, Cohen CI. Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia. Schizophr Res. 2008;106(2-3):348-355.
39. Ritchie CW, Harrigan S, Mastwyk M, Macfarlane S, Cheesman N, Ames D. Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: An open study of 3(1/2) years duration. Int J Geriatr Psychiatry. 2010;25(4):411-418.